Tertiapin-Q trifluoroacetate salt

Modify Date: 2024-01-03 13:02:55

Tertiapin-Q trifluoroacetate salt Structure
Tertiapin-Q trifluoroacetate salt structure
Common Name Tertiapin-Q trifluoroacetate salt
CAS Number 910044-56-3 Molecular Weight 2452.004
Density 1.5±0.1 g/cm3 Boiling Point N/A
Molecular Formula C106H175N35O24S4 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Tertiapin-Q trifluoroacetate salt


Tertiapin-Q is a highly selective blocker of GIRK1/4 heterodimer and ROMK1 (Kir1.1).

 Names

Name Tertiapin-Q
Synonym More Synonyms

 Tertiapin-Q trifluoroacetate salt Biological Activity

Description Tertiapin-Q is a highly selective blocker of GIRK1/4 heterodimer and ROMK1 (Kir1.1).
Related Catalog
Target

Potassium channel[1]

In Vitro Tertiapin-Q is a highly selective blocker of G protein-coupled inwardly rectifying potassium (GIRK1/4) heterodimer and renal outer medullary potassium channel (ROMK1, Kir1.1)[1]. Tertiapin-Q is a potent and selective blocker for Kir1.1 renal outer medullary potassium, Kir3.1-Kir3.4 channels and calcium activated large conductance potassium channels (big potassium channels). The somatostatin (SS-14)-activated current is almost completely blocked (93.2±2.9%, n=5; P<0.01) by preincubation with the G protein-coupled inwardly rectifying potassium (GIRK) channel blocker Tertiapin-Q (TPN-Q)[2].
In Vivo Tertiapin-Q is a muscarinic acetylcholine receptor-operated K+ current (IK,Ach) blocker. After the cessation of rapid atrial pacing, the atrial effective refractory period (AERP) is unchanged during the experimental period in the rapid atrial pacing (RAP) rabbits (n=6). Bepridil (1 mg/kg, n=5 for each group), Amiodarone (10 mg/kg, n=5 for each group), Vernakalant (3 mg/kg, n=5 for each group), Ranolazine (10 mg/kg, n=6 for each group) or Tertiapin-Q (0.03 mg/kg, n=5 for each group) on the AERP in the control and RAP rabbits. Tertiapin-Q significantly prolongs the AERP at each pacing cycle length both in the control and RAP rabbits. The extents of prolonging effect of Tertiapin-Q on the AERP in the RAP rabbits are greater than those in the control animals[3].
Animal Admin Rabbits[3] Male New Zealand White rabbits weighing 3.0-3.5 kg are used for this study. Effects of Vernakalant, Ranolazine and Tertiapin-Q on the atrial effective refractory period (AERP) in the control and rapid atrial pacing (RAP) rabbits. Vernakalant (left panels, 3 mg/kg, n=5 for each group), Ranolazine (middle panels; 10 mg/kg, n=6 for each group) or Tertiapin-Q (right panels; 0.03 mg/kg, n=5 for each group) is intravenously administered to the control or RAP rabbits. AERP is measured before and 10 min after the administration of each drug, which are shown in the lower panels.
References

[1]. Picton LD, et al. Mechanisms underlying the endogenous dopaminergic inhibition of spinal locomotor circuit function in Xenopus tadpoles. Sci Rep. 2016 Oct 20;6:35749.

[2]. Günther T, et al. Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay. Mol Endocrinol. 2016 Apr;30(4):479-90.

[3]. Chiba T, et al. Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits. J Pharmacol Sci. 2016 Mar;130(3):170-6.

 Chemical & Physical Properties

Density 1.5±0.1 g/cm3
Molecular Formula C106H175N35O24S4
Molecular Weight 2452.004
Exact Mass 2450.243164
LogP -9.12
Index of Refraction 1.693
Storage condition 2-8℃

 Synonyms

N-{[(1R,4S,7S,10S,16S,19S,22S,25S,28S,31R,36R,39S,42S,45S,52R,55S)-52-[(L-Alanyl-L-leucyl)amino]-39,42-bis(4-aminobutyl)-28,55-bis(2-amino-2-oxoethyl)-4-(3-amino-3-oxopropyl)-16,22-di[(2S)-2-butanyl]-19-sec-butyl-25-(3-carbamimidamidopropyl)-7-(1H-imidazol-4-ylmethyl)-45-(1H-indol-3-ylmethyl)-3,6,9,15,18,21,24,27,30,38,41,44,47,53,56-pentadecaoxo-33,34,49,50-tetrathia-2,5,8,14,17,20,23,26,29,37,40,43,46,54,57-pentadecaazatricyclo[29.16.10.0
L-Lysinamide, N-[[(3S,6S,9R,12S,15S,18S,21R,26R,29S,32S,35S,38S,41S,46aS,49S,52R)-15,18-bis(4-aminobutyl)-32-[3-[(aminoiminomethyl)amino]propyl]-29,49-bis(2-amino-2-oxoethyl)-6-(3-amino-3-oxopropyl)-52-[[(2S)-2-[[(2S)-2-amino-1-oxopropyl]amino]-4-methyl-1-oxopentyl]amino]tetratetracontahydro-3-(1H-imidazol-4-ylmethyl)-12-(1H-indol-3-ylmethyl)-35,41-bis[(1S)-1-methylpropyl]-38-(1-methylpropyl)-1,4,7,10,13,16,19,27,30,33,36,39,42,48,51-pentad